Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease

被引:23
作者
Chen, Dan-Qian [1 ]
Wu, Jun [2 ]
Li, Ping [3 ]
机构
[1] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China
[2] Shandong Coll Tradit Chinese Med, Yantai, Shandong, Peoples R China
[3] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
diabetic kidney disease; Chinese herbal medicine; therapeutic mechanism; clinical application; metabolism regulation; OXIDATIVE STRESS; ABELMOSCHUS-MANIHOT; PODOCYTE INJURY; NEPHROPATHY; EFFICACY; RECEPTOR; ALBUMINURIA; SALIDROSIDE; SAFETY; CANAGLIFLOZIN;
D O I
10.3389/fphar.2022.1055296
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic kidney disease (DKD) is the major complications of type 1 and 2 diabetes, and is the predominant cause of chronic kidney disease and end-stage renal disease. The treatment of DKD normally consists of controlling blood glucose and improving kidney function. The blockade of renin-angiotensin-aldosterone system and the inhibition of sodium glucose cotransporter 2 (SGLT2) have become the first-line therapy of DKD, but such treatments have been difficult to effectively block continuous kidney function decline, eventually resulting in kidney failure and cardiovascular comorbidities. The complex mechanism of DKD highlights the importance of multiple therapeutic targets in treatment. Chinese herbal medicine (active compound, extract and formula) synergistically improves metabolism regulation, suppresses oxidative stress and inflammation, inhibits mitochondrial dysfunction, and regulates gut microbiota and related metabolism via modulating GLP-receptor, SGLT2, Sirt1/AMPK, AGE/RAGE, NF-kappa B, Nrf2, NLRP3, PGC-1 alpha, and PINK1/Parkin pathways. Clinical trials prove the reliable evidences for Chinese herbal medicine against DKD, but more efforts are still needed to ensure the efficacy and safety of Chinese herbal medicine. Additionally, the ideal combined therapy of Chinese herbal medicine and conventional medicine normally yields more favorable benefits on DKD treatment, laying the foundation for novel strategies to treat DKD.
引用
收藏
页数:15
相关论文
共 140 条
[1]   SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review [J].
Alicic, Radica Z. ;
Johnson, Emily J. ;
Tuttle, Katherine R. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 72 (02) :267-277
[2]   Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKCβ/p66Shc axis and activation of FOXO-3a [J].
ALTamimi, Jozaa Z. ;
AlFaris, Nora A. ;
AL-Farga, Ammar M. ;
Alshammari, Ghedeir M. ;
BinMowyna, Mona N. ;
Yahya, Mohammed A. .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2021, 87
[3]   CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease [J].
Anders, Hans-Joachim ;
Huber, Tobias B. ;
Isermann, Berend ;
Schiffer, Mario .
NATURE REVIEWS NEPHROLOGY, 2018, 14 (06) :361-377
[4]   Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes [J].
Bakris, George L. ;
Agarwal, Rajiv ;
Anker, Stefan D. ;
Pitt, Bertram ;
Ruilope, Luis M. ;
Rossing, Peter ;
Kolkhof, Peter ;
Nowack, Christina ;
Schloemer, Patrick ;
Joseph, Amer ;
Filippatos, Gerasimos .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2219-2229
[5]   Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects [J].
Barrera-Chimal, Jonatan ;
Lima-Posada, Ixchel ;
Bakris, George L. ;
Jaisser, Frederic .
NATURE REVIEWS NEPHROLOGY, 2022, 18 (01) :56-70
[6]   Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets [J].
Barrera-Chimal, Jonatan ;
Jaisser, Frederic .
DIABETES OBESITY & METABOLISM, 2020, 22 :16-31
[7]   Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis [J].
Barrera-Chimal, Jonatan ;
Girerd, Sophie ;
Jaisser, Frederic .
KIDNEY INTERNATIONAL, 2019, 96 (02) :302-319
[8]   Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease [J].
Cansby, Emmelie ;
Caputo, Mara ;
Gao, Lei ;
Kulkarni, Nagaraj M. ;
Nerstedt, Annika ;
Stahlman, Marcus ;
Boren, Jan ;
Porosk, Rando ;
Soomets, Ursel ;
Pedrelli, Matteo ;
Parini, Paolo ;
Marschall, Hanns-Ulrich ;
Nystrom, Jenny ;
Howell, Brian W. ;
Mahlapuu, Margit .
JCI INSIGHT, 2020, 5 (24)
[9]   Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension [J].
Cappetta, Donato ;
Ciuffreda, Loreta Pia ;
Cozzolino, Anna ;
Esposito, Grazia ;
Scavone, Cristina ;
Sapio, Luigi ;
Naviglio, Silvio ;
D'Amario, Domenico ;
Crea, Filippo ;
Rossi, Francesco ;
Berrino, Liberato ;
De Angelis, Antonella ;
Urbanek, Konrad .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
[10]   Efficacy, safety and response predictors of adjuvant astragalus for diabetic kidney disease (READY): study protocol of an add-on, assessor-blind, parallel, pragmatic randomised controlled trial [J].
Chan, Kam Wa ;
Kwong, Alfred Siu Kei ;
Tsui, Pun Nang ;
Cheung, Simon Chi Yuen ;
Chan, Gary Chi Wang ;
Choi, Wing Fai ;
Yiu, Wai Han ;
Zhang, Yanbo ;
Wong, Michelle Man-Ying ;
Zhang, Zhang-Jin ;
Tan, Kathryn Choon Beng ;
Lao, Lixing ;
Tang, Sydney Chi Wai .
BMJ OPEN, 2021, 11 (01)